121 related articles for article (PubMed ID: 1108198)
1. BCG inhibition of murine leudemia: local suppression and systemic tumor immunity require different doses.
Bartlett GL; Purnell DM; Kreider JW
Science; 1976 Jan; 191(4224):299-301. PubMed ID: 1108198
[TBL] [Abstract][Full Text] [Related]
2. Relationship between intradermal tumor suppression and tumor immunity.
Bartlett GL; Kreider JW; Purnell DM
J Natl Cancer Inst; 1976 Dec; 57(6):1297-303. PubMed ID: 794505
[TBL] [Abstract][Full Text] [Related]
3. BCG immunization for the lymphoid leukemia line (LSTRA) in CDF1 mice.
Chaparas SD; Chirigos M; Pearson J; Sher N
Natl Cancer Inst Monogr; 1973 Dec; 39():87-8. PubMed ID: 4595328
[No Abstract] [Full Text] [Related]
4. Potentiation of immunity to murine leukemia (LSTRA) by Bacillus Calmette-Guérin.
Bartlett GL; Kreider JW; Purnell DM
Cancer Res; 1978 Dec; 38(12):4401-8. PubMed ID: 719627
[No Abstract] [Full Text] [Related]
5. The antileukemic effect of systemic non-specific BCG-immunostimulation vs systemic specific immunostimulation with irradiated isogeneic leukemic cells.
Olsson L; Ebbesen P; Kiger N; Florentin I; Mathé G
Eur J Cancer (1965); 1978 Apr; 14(4):355-62. PubMed ID: 348478
[No Abstract] [Full Text] [Related]
6. Enhancement of immunity against murine syngeneic tumors by a fraction extracted from non-pathogenic mycobacteria.
Lamensans A; Chedid L; Lederer E; Rosselet JP; Gustafson RH; Spencer HJ; Ludwig B; Berger FM
Proc Natl Acad Sci U S A; 1975 Sep; 72(9):3656-60. PubMed ID: 171670
[TBL] [Abstract][Full Text] [Related]
7. Immunopotentiation with BCG. 3. Modulation of the response to a tumor-specific antigen.
Hawrylko E; Mackaness GB
J Natl Cancer Inst; 1973 Nov; 51(5):1677-82. PubMed ID: 4587142
[No Abstract] [Full Text] [Related]
8. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
Vaage J
Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
[TBL] [Abstract][Full Text] [Related]
9. Stimulating influence of bacillus Calmette-Guérin on immunity to polyoma tumors and spontaneous leukemia.
Lemonde P; Dubreuil R; Guindon A; Lussier G
J Natl Cancer Inst; 1971 Nov; 47(5):1013-24. PubMed ID: 4330795
[No Abstract] [Full Text] [Related]
10. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
[TBL] [Abstract][Full Text] [Related]
11. Attempts to prevent acquired immunological insufficiencies in mice by bacillus Calmette-Guerin.
Amiel JL; Berardet M
Experientia; 1971 Aug; 27(8):941-3. PubMed ID: 4947883
[No Abstract] [Full Text] [Related]
12. A cytokinetic analysis of bacillus calmette-guérin-induced growth control of a murine leukemia.
Olsson L; Mathé G
Cancer Res; 1977 Jun; 37(6):1743-9. PubMed ID: 322860
[TBL] [Abstract][Full Text] [Related]
13. Immunopotentiation with BCG. IV. Factors affecting the magnitude of an antitumor response.
Hawrylko E; Mackaness GB
J Natl Cancer Inst; 1973 Nov; 51(5):1683-8. PubMed ID: 4587143
[No Abstract] [Full Text] [Related]
14. Virus tumorigenesis and immunity: influence of immunostimulation and immunodepression.
Friedman H; Ceglowski WS
Johns Hopkins Med J Suppl; 1974; 3():187-209. PubMed ID: 4609083
[No Abstract] [Full Text] [Related]
15. Immunization of mice after airborne infection with various strains of BCG.
Lefford MJ
Am Rev Respir Dis; 1978 Jan; 117(1):103-9. PubMed ID: 339795
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of cancer with cell wall skeleton of Myocabacterium bovis-Bacillus Calmette-Guérin: experimental and clinical results.
Yamamura Y; Azuma I; Taniyama T; Sugimura K; Hirao F; Tokuzen R; Okabe M; Nakahara W; Yasumoto K; Ohta M
Ann N Y Acad Sci; 1976; 277(00):209-27. PubMed ID: 826205
[TBL] [Abstract][Full Text] [Related]
17. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.
Shima J; Yoshioka T; Nakajima H; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1988; 26(1):43-7. PubMed ID: 2964268
[TBL] [Abstract][Full Text] [Related]
18. Nonspecific macrophage activation by systemic adjuvants. Evaluation by lysosomal enzyme and in vitro tumoricidal activities.
Bruley-Rosset M; Florentin I; Khalil AM; Mathé G
Int Arch Allergy Appl Immunol; 1976; 51(5):594-607. PubMed ID: 786904
[TBL] [Abstract][Full Text] [Related]
19. [Effects of B.C.G. on the hepatic catalase activity in mouse. Relation between the reticuloendothelial system and the resistance against grafted AKR leukemia].
Lamensans A; Mollier MF; Laurent M
Rev Fr Etud Clin Biol; 1968 Nov; 13(9):871-6. PubMed ID: 4885127
[No Abstract] [Full Text] [Related]
20. An endotoxin-induced serum factor that causes necrosis of tumors.
Carswell EA; Old LJ; Kassel RL; Green S; Fiore N; Williamson B
Proc Natl Acad Sci U S A; 1975 Sep; 72(9):3666-70. PubMed ID: 1103152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
